Novel assessment of platelet-rich plasma treatment shows efficacy in
patients with osteoarthritis

Date:
August 30, 2021
Source:
Baylor College of Medicine
Summary:
A pilot study combined wearable technology and patient-reported
outcomes to assess the efficacy of platelet-rich plasma (PRP)
treatment in osteoarthritis (OA), finding significant improvements.



FULL STORY ==========================================================================
A pilot study conducted by researchers at Baylor College of Medicine
combined wearable technology and patient-reported outcomes to assess the efficacy of platelet-rich plasma (PRP) treatment in osteoarthritis (OA).


==========================================================================
The results, published in the journal Regenerative Medicine, showed
that a single injection of leukocyte-rich/PRP in the knee joint
significantly improved functional mobility, pain and quality of life
after six weeks. The study supports using this combined approach to
further evaluate this and other emerging biological therapies for musculoskeletal disorders in larger clinical trials.

"OA is a leading cause of disabilities, affecting nearly 52 million
Americans," said first and corresponding author Dr. Prathap Jayaram,
director of regenerative sports medicine and assistant professor in the Department of Physical Medicine and Rehabilitation and Orthopedic Surgery
at Baylor. "It has been estimated that more than 80% of individuals older
than 55 years have some X-ray-based evidence of the disease." OA develops
when the smooth cushion between bones, the cartilage, breaks down.

Progressively, joints become painful, swollen and hard to move, Jayaram explained. Currently, there are no validated therapies that delay disease progression. The current standard of care is limited to the alleviation
of symptoms with corticosteroids.

"However, although steroids seem to be helpful in the short term for
pain, emerging evidence has associated steroid long-term use in OA with
loss of cartilage," Jayaram said. "As OA is a whole joint disease, there
is a need for developing novel therapeutic strategies that ultimately
prevent and/or delay disease progression while improving functional
outcomes. PRP is emerging as one of the promising candidates to treat OA
that are currently being used in clinical practice." Combining wearable technology and patient assessment to evaluate the treatment One challenge
of previous studies assessing PRP therapies in OA is that treatment
evaluation is based on patient-reported outcomes that subjectively
assess pain or aspects of joint function, such as the time up-and-go
(TUG), how quick a person gets up from a chair.

In this study, Jayaram and colleagues incorporated wearable technology
to objectively assess functional outcomes such as TUG, in addition to
patient- reported outcomes to comprehensively evaluate the efficacy of
PRP in knee OA (KOA).

The prospective pilot study included 12 patients diagnosed with KOA. Each patient received one ultrasound-guided injection of PRP and function
and pain were evaluate six weeks later.

PRP is prepared from the patient's own blood by removing the red
blood cells and enriching the concentration of platelets. PRP also
contains white blood cells, or leukocytes. PRPs are formulated either leucocyte-rich (LR) or leukocyte-poor. A preclinical study by Jayaram
and his colleagues had previously shown that LR-PRP had potential disease-modifying effects that correlated with functional outcomes.

"In the current study, we found that a single injection of LR-PRP
into the knee does significantly improve functional mobility,
pain and quality of life at six weeks," Jayaram said. "To our
knowledge, our study is the first to report the efficacy of
LR-PRP on objective functional outcomes using wearable sensor
technology and validated patient-reported outcomes. Our findings
provide the basis to conduct larger randomized clinical trials of PRP." ========================================================================== Story Source: Materials provided by Baylor_College_of_Medicine. Original written by Homa Shalchi. Note: Content may be edited for style and length.


========================================================================== Journal Reference:
1. Prathap Jayaram, Gu Eon Kang, Brett L Heldt, Olumide Sokunbi,
Bo Song,
Peter C Yeh, Max Epstein, Theodore B Shybut, Brendan H Lee,
Bijan Najafi.

Novel assessment of leukocyte-rich platelet rich plasma on
functional and patient reported outcomes in knee osteoarthritis:
a pilot study.

Regenerative Medicine, 2021; DOI: 10.2217/rme-2021-0032 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2021/08/210830163952.htm

--- up 16 weeks, 3 days, 22 hours, 45 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)